The randomized phase III BEACON (BRAF, EGFR, and MEK inhibition in BRAF V600E-mutant CRC) trial demonstrated that the combination of a selective BRAF inhibitor with an EGFR antibody (encorafenib plus cetuximab), with or without a MEK inhibitor, improved response rates and overall survival compared with standard chemotherapy in previously treated patients, establishing targeted BRAF + EGFR inhibition as a standard option in the refractory setting [49]. Here, MAP2K7 is linked to colorectal carcinoma.